Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer

Trial Profile

Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs CV 301 (Primary) ; MSB 0011359C (Primary) ; Rilimogene galvacirepvec-rilimogene glafolivec (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 16 Mar 2018 Planned initiation date changed from 02 Mar 2018 to 22 Mar 2018.
    • 27 Feb 2018 Planned initiation date changed from 28 Feb 2018 to 2 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top